Jim Simons
GBT

Jim Simons’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Jim Simons’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-283,700
Closed -$19.3M – 4584
2022
Q3 		$19.3M Buy
+283,700
New +$15.6M 0.03% 691
2022
Q1 		– Sell
-8,935
Closed -$262K – 4614
2021
Q4 		$262K Sell
8,935
-76,426
-90% -$2.37M ﹤0.01% 3404
2021
Q3 		$2.17M Buy
85,361
+34,681
+68% +$1.02M ﹤0.01% 2026
2021
Q2 		$1.77M Buy
+50,680
New +$1.98M ﹤0.01% 2335
2020
Q3 		– Sell
-50,400
Closed -$3.18M – 3800
2020
Q2 		$3.18M Buy
50,400
+42,300
+522% +$2.9M ﹤0.01% 1905
2020
Q1 		$414K Buy
+8,100
New +$543K ﹤0.01% 2850
2018
Q3 		– Sell
-217,700
Closed -$9.84M – 3637
2018
Q2 		$9.84M Sell
217,700
-394,100
-64% -$17.9M 0.01% 1362
2018
Q1 		$29.6M Buy
+611,800
New +$34.1M 0.03% 707
2017
Q4 		– Sell
-186,400
Closed -$5.79M – 3556
2017
Q3 		$5.79M Buy
+186,400
New +$5.24M 0.01% 1679
2016
Q4 		– Sell
-101,200
Closed -$2.33M – 3541
2016
Q3 		$2.33M Buy
+101,200
New +$1.93M ﹤0.01% 2097

Other funds holding GBT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Jim Simons's GBT Position: Q4 2022 in Review

Jim Simons sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 283,700 shares — an estimated $19.3M sold.

Jim Simons first reported a position in GBT in Q3 2016 and held it in 10 quarters. The position peaked at $29.6M in Q1 2018. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

  • Jim Simons reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • Jim Simons sold 283,700 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $19.3M.
  • Jim Simons first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 10 quarters.
  • Jim Simons's Global Blood Therapeutics, Inc. position peaked at $29.6M in Q1 2018.
  • 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.